Anemia
News
Research may help explain how VOCs occur
Researchers say they have gained new insight that may help explain how vaso-occlusive crises (VOCs) occur in patients with sickle cell disease (...
News
AMP publishes report on DNA variants in CMNs
A new report addresses the clinical relevance of DNA variants in chronic myeloid neoplasms (CMNs). The report is intended to aid clinical...
Feature
Blood disorders researcher is finalist for Trailblazer Prize
Dr. Daniel Bauer of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, was recognized for his research on sickle cell disease and...
News
FDA grants priority review to drug for PNH
The US Food and Drug Administration (FDA) has accepted for priority review the biologics license application (BLA) for ALXN1210, a long-acting C5...
Conference Coverage
Integrated pain program reduced LOS for sickle cell patients
WASHINGTON – The small study is another data point showing the importance of multidisciplinary care.
News
Partial hold placed on trial of drug for AML, MDS
The US Food and Drug Administration (FDA) has placed a partial clinical hold on a phase 1b/2 study of OXi4503, a vascular disrupting agent. In...
News
Auto-HSCT linked to higher AML, MDS risk
Patients undergoing autologous hematopoietic stem cell transplant (auto-HSCT) for lymphoma or myeloma have an increased risk of acute myeloid...
News
Familial risk of myeloid malignancies
A large study has revealed “the strongest evidence yet” supporting genetic susceptibility to myeloid malignancies, according to a researcher. The...
News
FA pathway key to DNA repair after CRISPR cutting
New research suggests the Fanconi anemia (FA) pathway plays a key role in repairing double-strand breaks (DSBs) created by CRISPR-Cas9 genome...
News
CHMP recommends generic deferiprone
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Deferiprone Lipomed to treat...
News
CHMP supports expanded approval for epoetin alfa products
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended a change to the terms of marketing...